Saturday , June 25 2022

Horizon Discovery licenses CHOSOURCE to Sanyou Biopharmaceuticals Co.


Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, announced today that it has granted Sanyou Biopharmaceuticals Co. two commercial licenses for its cGMP-compliant CHOSOURCE ™ platform, Ltd., a leading leader. a biotechnology company focused on research, development and delivery of integrated solutions for innovative antibody drug developments.

Sanyou will use the Chinese K1 Hamster Ovary (CHO) cell line edited by Horizon genes for the development of pre-clinical antibody drug projects and also to support the clinical development and commercialization of its cus tomers human biotherapeutic products. as offering the platform through its contract research services.

Sanyou takes the lead a biotech company with extensive experience in early-stage drug discovery, IND filing, and clinical trial management. The Company has established an innovative integrated antibody R&D laboratory and we are pleased that CHOSOURCE has been selected to support its biotherapeutic pipeline and contract research services offering, ”

Jesús Zurdo, Global Bioproduction Business Unit, Horizon Discovery.

“Horizon is committed to supporting innovative organizations of all sizes to empower biotherapeutic production using our expression platform. We are proud to have licensed CHOSOURCE to over 80 organizations, from not-for-profit and early stage start-ups to clinical stage biotechnology and large pharmaceutical companies, and helped enable at least 8 biotherapies expressed in these cells to progress to trials clinical. ”

CHOSOURCE Horizon facilitates the development of stable cell lines for the expression of antibodies and other recombinant proteins, and is recognized in the industry and by regulators for high-product manufacturing. This robust platform will be instrumental in enabling us to produce stable cell lines for the development of antibody drugs, diagnostic products and components related to cell therapy, and allow us to provide our clients with a stronger one-stop solution with IND-ready projects through our contract research services and pipeline enrichment collaborations. ”

David Lang, CEO, Sanyou Biopharmaceuticals Co., Ltd.

Horizon’s proprietary GS cell line and protocols have a proven track record of biopharmaceutical discovery and development, from the provisional expression for research applications to the development of stable cell lines for clinical and commercial biotherapeutics production, including new multi-specific and new complex molecular architecture.

The Company licenses its CHOSOURCE expression system to pharmaceutical, biotechnology, and biotech companies, as well as contract manufacturing organizations.

For more information on Horizon’s CHO expression system visit:

Source link